Prime Medicine, Inc.

Prime Medicine is a biotechnology company developing genetic therapies based on Prime Editing, a gene-editing platform designed to correct disease-causing mutations without creating double-stranded DNA breaks. The company's technology comprises a modified Cas domain paired with a reverse transcriptase domain that directly copies edited DNA sequences into target genomic sites, along with pegRNA molecules that direct the Prime Editor to specific genomic locations. This approach aims to address a spectrum of genetic diseases with potentially fewer off-target effects than conventional gene-editing methods.

The company is advancing its pipeline through internal research programs and external collaborations. Prime Medicine has established a research collaboration with Cimeio Therapeutics focused on developing Prime Edited Shielded-Cell & Immunotherapy Pairs, with applications in genetic diseases and hematologic malignancies including acute myeloid leukemia and myelodysplastic syndrome. The company remains in the research and development phase, with no disclosed revenue streams from approved or marketed therapies.

Prime Medicine operates with approximately 214 full-time employees and is headquartered in Cambridge, Massachusetts. The company was incorporated in Delaware in 2019 and is listed on Nasdaq. Its operations are primarily based in the United States.